HBP Share Price

Open 0.96 Change Price %
High 0.96 1 Day 0.00 0.00
Low 0.96 1 Week -0.02 -2.04
Close 0.96 1 Month -0.34 -26.15
Volume 200 1 Year -1.04 -52.00
52 Week High 2.25
52 Week Low 0.96
HBP Important Levels
Resistance 2 0.96
Resistance 1 0.96
Pivot 0.96
Support 1 0.96
Support 2 0.96
TSE Canada Most Active Stocks
TD 66.80 0.18%
TD 66.80 0.18%
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
DNT 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
GLG 0.34 9.68%
More..
TSE Canada Top Losers Stocks
TPL 0.02 -33.33%
TPL 0.02 -33.33%
LRT-UN 0.03 -25.00%
GBV 0.46 -24.59%
YRB-A 0.08 -11.11%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
CTU-A 0.19 -9.52%
E 0.31 -8.82%
More..

Helix BioPharma Corp (TSE: HBP)

HBP Technical Analysis 5
As on 24th Apr 2017 HBP Share Price closed @ 0.96 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.71 & Strong Sell for SHORT-TERM with Stoploss of 1.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
HBP Target for April
1st Target up-side 1.26
2nd Target up-side 1.39
3rd Target up-side 1.51
1st Target down-side 0.9
2nd Target down-side 0.77
3rd Target down-side 0.65
HBP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.helixbiopharma.com
HBP Address
HBP
305 Industrial Parkway South
Unit 3
Aurora, ON L4G 6X7
Canada
Phone: 905-841-2300
Fax: 905-841-2244
Interactive Technical Analysis Chart Helix BioPharma Corp ( HBP TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Helix BioPharma Corp
HBP Business Profile
Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.